Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for preeclampsia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on preeclampsia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on preeclampsia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
three controlled studies. Clinical effectiveness Two studies including 1706 women with suspected preeclampsia showed that PlGF tests may reduce the time to preeclampsia diagnosis (median time to pre-eclampsia diagnosis, days time ratio 0.36 (95% CI 0.15-0.87)), and may reduce the risk of severe adverse maternal outcomes (adjusted OR 0.32 (95% CI 0.11-0.96)). We are uncertain whether sFlt-1/PlGF or PlGF testing improve neonatal outcomes. Health services utilisation One randomised controlled trial (...) of maternal organ dysfunction. Symptoms of preeclampsia are strong headache, visual disturbance, epigastric pain, swelling of hands, face or feet and low output of urine. Preeclampsia may develop rapidly to seizure (eclampsia), HELLP syndrome (haemolysis, elevated liver enzymes and low platelets), stroke, disseminated intravascular coagulation (DIC) and organ failure. Therefore, preeclampsia is regarded as a life-threatening condition that requires hospital admission and close maternal and fetal
To read this article in full you will need to make a payment Already a print subscriber? Already an online subscriber? Register: Institutional Access: References Ananth C.V. Keyes K.M. Wapner R.J. Pre-eclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ. 2013; 347 : f6564 Petersen E.E. Davis N.L. Goodman D. et al. Vital signs: pregnancy-related deaths, United States, 2011–2015, and strategies for prevention, 13 states, 2013–2017. MMWR Morb Mortal Wkly Rep. 2019; 68 : 423 (...) -429 Rossi R.M. Hall E. Dufendach K. DeFranco E.A. Predictive model of factors associated with maternal intensive care unit admission. Obstet Gynecol. 2019; 134 : 216-224 Wall-Wieler E. Carmichael S.L. Gibbs R.S. et al. Severe maternal morbidity among stillbirth and live birth deliveries in California. Obstet Gynecol. 2019; 134 : 310-317 Ananth C.V. Lavery J.A. Friedman A.M. Wapner R.J. Wright J.D. Serious maternal complications in relation to severe pre-eclampsia: a retrospective cohort study
Gestational Hypertension and Preeclampsia Gestational Hypertension and Preeclampsia | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Gestational Hypertension and Preeclampsia Practice Bulletin Number 222 June 2020 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions. . In Latin America and the Caribbean, hypertensive disorders are responsible for almost 26 (...) % of maternal deaths, whereas in Africa and Asia they contribute to 9% of deaths. Although maternal mortality is much lower in high-income countries than in developing countries, 16% of maternal deaths can be attributed to hypertensive disorders . In the United States, the rate of preeclampsia increased by 25% between 1987 and 2004 . Moreover, in comparison with women giving birth in 1980, those giving birth in 2003 were at 6.7-fold increased risk of severe preeclampsia . This complication is costly: one
WHO recommendation on Calcium supplementation before pregnancy for the prevention of pre-eclampsia and its complications WHO recommendation on Calcium supplementation before pregnancy for the prevention of pre-eclampsia and its complicationsWHO recommendation on Calcium supplementation before pregnancy for the prevention of pre-eclampsia and its complicationsWHO recommendation on calcium supplementation before pregnancy for the prevention of pre-eclampsia and its complications ISBN 978-92-4 (...) . The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO recommendation on calcium supplementation before pregnancy for the prevention of pre-eclampsia and its complications. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data
Planned earlier delivery for late pre-eclampsia may be better for mothers. The studyChappell LC, Brocklehurst P, Green ME, et al. Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial. Lancet 2019;394:1181-90.This project was funded by the NIHR Health Technology Assessment Programme (project number 12/25/03).To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000838/mothers-benefit-from-a-planned (...) -earlier-delivery-for-late-pre-eclampsia.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Hypertension in pregnancy: Scenario: Pre-eclampsia Scenario: Pre-eclampsia | Management | Hypertension in pregnancy | CKS | NICE Search CKS… Menu Scenario: Pre-eclampsia Hypertension in pregnancy: Scenario: Pre-eclampsia Last revised in October 2019 Scenario: Pre-eclampsia From age 13 years onwards (Female). How do I manage a woman at high risk of, or exhibiting clinical features of pre-eclampsia? Note: The National Institute of Health and Care Excellence (NICE) defines pre-eclamsia as new (...) complications such as eclampsia, altered mental status, blindness, stroke, clonus, severe headaches or persistent visual scotomata. Haematological complications such as thrombocytopenia (platelet count below 150,000/microlitre), disseminated intravascular coagulation or haemolysis. Uteroplacental dysfunction such as fetal growth restriction, abnormal umbilical artery doppler waveform analysis, or stillbirth. Be aware that women are considered to be at high risk of pre-eclampsia if they have: One
Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial. In women with late preterm pre-eclampsia, the optimal time to initiate delivery is unclear because limitation of maternal disease progression needs to be balanced against infant complications. The aim of this trial was to determine whether planned earlier initiation of delivery reduces maternal adverse outcomes without substantial worsening of neonatal or infant outcomes (...) , compared with expectant management (usual care) in women with late preterm pre-eclampsia.In this parallel-group, non-masked, multicentre, randomised controlled trial done in 46 maternity units across England and Wales, we compared planned delivery versus expectant management (usual care) with individual randomisation in women with late preterm pre-eclampsia from 34 to less than 37 weeks' gestation and a singleton or dichorionic diamniotic twin pregnancy. The co-primary maternal outcome was a composite
2019LancetControlled trial quality: predicted high
Long term follow up of biomarkers of podocyte damage and renal function in patients with and without preeclampsia. preeclampsia can be associated with future renal disease.To measure changes in renal function overtime in patients with preeclampsia.urine and serum samples from eleven patients with preeclampsia and eight patients with a normal pregnancy were obtained during pregnancy, postpartum, and 3 years after delivery. Urine podocalyxin, protein, and serum creatinine were measured.after 3 (...) years, there were no significant differences in urinary podocalyxin in patients with or without preeclampsia: 4.34 ng/mg [2.69, 8.99] vs. 7.66 ng/mg [2.35, 13], p = 0.77. The same applied to urinary protein excretion: 81.5 mg/g [60.6, 105.5] vs. 43.2 mg/g [20.9, 139.3] p = 0.23. Serum creatinine was 0.86 mg/dL [0.7, 0.9] vs. 0.8 mg/dL [0.68, 1] p = 0.74 in those with and without preeclampsia. In normal patients, urinary podocalyxin decreased from 54.4 ng/mg [34.2, 76.9] during pregnancy to 7.66 ng
Pre-eclampsia: pathophysiology and clinical implications. Pre-eclampsia is a common disorder that particularly affects first pregnancies. The clinical presentation is highly variable but hypertension and proteinuria are usually seen. These systemic signs arise from soluble factors released from the placenta as a result of a response to stress of syncytiotrophoblast. There are two sub-types: early and late onset pre-eclampsia, with others almost certainly yet to be identified. Early onset pre (...) -eclampsia arises owing to defective placentation, whilst late onset pre-eclampsia may center around interactions between normal senescence of the placenta and a maternal genetic predisposition to cardiovascular and metabolic disease. The causes, placental and maternal, vary among individuals. Recent research has focused on placental-uterine interactions in early pregnancy. The aim now is to translate these findings into new ways to predict, prevent, and treat pre-eclampsia.Published by the BMJ
Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Previous prospective cohort studies have shown that angiogenic factors have a high diagnostic accuracy in women with suspected pre-eclampsia, but we remain uncertain of the effectiveness of these tests in a real-world setting. We therefore aimed to determine whether knowledge of the circulating concentration of placental growth factor (PlGF (...) ), an angiogenic factor, integrated with a clinical management algorithm, decreased the time for clinicians to make a diagnosis in women with suspected pre-eclampsia, and whether this approach reduced subsequent maternal or perinatal adverse outcomes.We did a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial in 11 maternity units in the UK, which were each responsible for 3000-9000 deliveries per year. Women aged 18 years and older who presented with suspected pre-eclampsia between 20
2019LancetControlled trial quality: predicted high
Pre-eclampsia and risk of later kidney disease: nationwide cohort study. To investigate associations between pre-eclampsia and later risk of kidney disease.Nationwide register based cohort study.Denmark.All women with at least one pregnancy lasting at least 20 weeks between 1978 and 2015.Hazard ratios comparing rates of kidney disease between women with and without a history of pre-eclampsia, stratified by gestational age at delivery and estimated using Cox regression.The cohort consisted of 1 (...) 072 330 women followed for 19 994 470 person years (average 18.6 years/woman). Compared with women with no previous pre-eclampsia, those with a history of pre-eclampsia were more likely to develop chronic renal conditions: hazard ratio 3.93 (95% confidence interval 2.90 to 5.33, for early preterm pre-eclampsia (delivery <34 weeks); 2.81 (2.13 to 3.71) for late preterm pre-eclampsia (delivery 34-36 weeks); 2.27 (2.02 to 2.55) for term pre-eclampsia (delivery ≥37 weeks). In particular, strong
Predictive performance of the competing risk model in screening for preeclampsia The established method of screening for preeclampsia is to identify risk factors from maternal demographic characteristics and medical history; in the presence of such factors the patient is classified as high risk and in their absence as low risk. However, the performance of such an approach is poor. We developed a competing risks model, which allows combination of maternal factors (age, weight, height, race (...) , parity, personal and family history of preeclampsia, chronic hypertension, diabetes mellitus, systemic lupus erythematosus or antiphospholipid syndrome, method of conception and interpregnancy interval), with biomarkers to estimate the individual patient-specific risks of preeclampsia requiring delivery before any specified gestation. The performance of this approach is by far superior to that of the risk scoring systems.The objective of the study was to examine the predictive performance
Effectiveness of psycho-educational counseling on anxiety in preeclampsia. Preeclampsia is a serious complication during pregnancy that not only influences maternal and fetal physical health, but also has maternal mental health outcomes such as anxiety. Prenatal anxiety has negative short- and long-term effects on pre- and postpartum maternal mental health, delivery, and mental health in subsequent pregnancies.To investigate the effectiveness of individual psycho-educational counseling (...) on anxiety in pregnant women with preeclampsia.This was a randomized, intervention-controlled study involving two governmental hospitals in the municipality of Sirjan, Kerman, from January 30 2017 to March 31 2017. A total of 44 pregnant women with preeclampsia were assessed. The women were randomized into two groups: control (n=22) and intervention (n=22). The intervention consisted of two sessions of individual psycho-educational counseling. The level of anxiety was measured using the Spielberger State
Gestational Hypertension and Preeclampsia Gestational Hypertension and Preeclampsia | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Gestational Hypertension and Preeclampsia Practice Bulletin Number 202 January 2019 Jump to Resources Share Nonmembers: Subscribe now to access exclusive ACOG Clinical content, including: ACOG Clinical is designed for easy and convenient access to the latest clinical
Torsemide for Prevention of Persistent Postpartum Hypertension in Women With Preeclampsia: A Randomized Controlled Trial To evaluate whether torsemide reduces the rate of persistent postpartum hypertension in women with preeclampsia.We conducted a randomized, double-blind, placebo-controlled trial of women with preeclampsia at a tertiary center from August 2016 to September 2017. Those with gestational hypertension or renal or cardiopulmonary failure were excluded. Within 24 hours of delivery (...) , women were randomized one to one to oral torsemide, 20 mg/d, or placebo, for 5 days. Our primary outcome was blood pressure greater than or equal to 150 mm Hg systolic or 100 mm Hg diastolic (or both) on two occasions at least 4 hours apart by postpartum day 5 or by the time of hospital discharge. Assuming a 50% rate of persistent hypertension in women with preeclampsia, 118 participants were required to detect a 50% rate reduction. Analyses were by intention to treat.From August 2016 to September
Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial Preterm preeclampsia has a high rate of fetal death or disability. There is no treatment to slow the disease, except delivery. Preclinical studies have identified proton pump inhibitors as a possible treatment.The purpose of this study was to examine whether esomeprazole could prolong pregnancy in women who have received a diagnosis of preterm preeclampsia.We performed a double-blind, randomized (...) controlled trial at Tygerberg Hospital in South Africa. Women with preterm preeclampsia (gestational age 26 weeks+0 days to 31 weeks+6 days) were assigned randomly to 40-mg daily esomeprazole or placebo. The primary outcome was a prolongation of gestation of 5 days. Secondary outcomes were maternal and neonatal outcomes. We compared circulating markers of endothelial dysfunction that was associated with preeclampsia and performed pharmacokinetic studies.Between January 2016 and April 2017, we recruited
Pre-eclampsia and risk of dementia later in life: nationwide cohort study. To explore associations between pre-eclampsia and later dementia, overall and by dementia subtype and timing of onset.Nationwide register based cohort study.Denmark.All women with at least one live birth or stillbirth between 1978 and 2015.Hazard ratios comparing dementia rates among women with and without a history of pre-eclampsia, estimated using Cox regression.The cohort consisted of 1 178 005 women with 20 352 695 (...) person years of follow-up. Women with a history of pre-eclampsia had more than three times the risk of vascular dementia (hazard ratio 3.46, 95% confidence interval 1.97 to 6.10) later in life, compared with women with no history of pre-eclampsia. The association with vascular dementia seemed to be stronger for late onset disease (hazard ratio 6.53, 2.82 to 15.1) than for early onset disease (2.32, 1.06 to 5.06) (P=0.08). Adjustment for diabetes, hypertension, and cardiovascular disease attenuated
Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. To determine the efficacy of high dose folic acid supplementation for prevention of pre-eclampsia in women with at least one risk factor: pre-existing hypertension, prepregnancy diabetes (type 1 or 2), twin pregnancy, pre-eclampsia in a previous pregnancy, or body mass index ≥35.Randomised, phase III, double blinded international (...) , multicentre clinical trial.70 obstetrical centres in five countries (Argentina, Australia, Canada, Jamaica, and UK).2464 pregnant women with at least one high risk factor for pre-eclampsia were randomised between 2011 and 2015 (1144 to the folic acid group and 1157 to the placebo group); 2301 were included in the intention to treat analyses.Eligible women were randomised to receive either daily high dose folic acid (four 1.0 mg oral tablets) or placebo from eight weeks of gestation to the end of week 16
. Preeclampsia and Eclampsia (Treatment) Preeclampsia : Practice Essentials, Overview, Pathophysiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cDovL2VtZWRpY2luZS5tZWRzY2FwZS5jb20vYXJ0aWNsZS8xNDc2OTE5LW92ZXJ2aWV3 processing > Preeclampsia Updated: Sep 15 (...) , 2016 (...) Hospital (...) ClinicalTrials.gov Identifier: NCT02214186 First received: July 16, 2014 Last updated: January 16, 2017 Last verified: July 2014 Full Text View Purpose Introduction: Pre-eclampsia is a multifactorial syndrome which occurs in hypertension and proteinuria in pregnant women over 20 weeks gestation. It is the leading cause of maternal complications such as pulmonary edema, which occurs in about 3% of severe preeclamptic having as one of the causes volume overload. Anesthetic procedures